Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Data like COACH trial results may help expand the range of options individuals and families consider as they weigh what matters most to them in achondroplasia treatment

  80% confidence

• Once-weekly TransCon CNP has demonstrated its potential to transform the treatment of achondroplasia, positioning it as a potential long-term foundation of care

  80% confidence

• The combination data underscore the potential of TransCon CNP to become the backbone therapy for addressing the underlying biology of achondroplasia, with TransCon hGH providing complementary benefit

  80% confidence

• The COACH Trial has demonstrated unmatched improvements in growth and benefits beyond linear growth without compromising safety or tolerability compared to historical data

  80% confidence

• Rational dual-agent regimens such as TransCon CNP and TransCon hGH combination may become a new standard of care in achondroplasia and other growth disorders

  80% confidence

• It is encouraging to see meaningful improvements in arm span and body proportionality alongside changes in linear height, as these endpoints provide important context beyond height alone

  80% confidence

• Combination therapy with TransCon CNP and TransCon hGH may set new treatment standards with clinically meaningful improvements in growth, body proportionality, and arm span with a safety and tolerability profile essential for long-term use in children

  80% confidence